

SECTION K ANAEMIA


The anaemia audit was performed in May 2016; all patients in Scotland receiving hospital or home haemodialysis on 01 May 2016 were included in the audit. Results were excluded for patients who had received a recent blood transfusion. There were 1796 results from 1878 patients (95.6%).

Haemoglobin concentration (Hb) was measured in a pre-dialysis blood sample after the first short interdialytic gap of the audit week, or as soon as possible thereafter. Auditing after the short (2 day) gap is done in order to minimise the potential effect of dilution due to fluid overload.

The UK Renal Association (UKRA) guideline from November 2010 recommends a target Hb of 100-120g/L for patients with chronic kidney disease, but only for those patients receiving Erythropoiesis Stimulating Agents (ESA) therapy.

We have reported the mean achieved Hb value by satellite unit where data are available and also the percentage of patients, by parent unit, achieving the UKRA standard.

K1 Mean Hb of Hospital HD patients in each dialysis unit May 2016



Patients with Hb >120g/L and confirmed as not receiving ESA therapy (103 patients) are excluded from the funnel plot. All units lie within 3 standard deviations of the population mean (109.8g/L) with the exception of VHK and MONK which fall more than 3SD above and below the mean respectively.

K2 Number of HD patients, median Hb and achievement of audit standards by renal unit May 2016											
	ARI	XH	DGRI	GLAS	MONK	NINE	RAIG	RHC*	RIE	VHK	Scotland
Number of patients	220	128	52	592	193	184	90	9	272	138	1878
Missing data or transfused	3	6	3	34	11	12	9	0	2	2	82
% patients with Hb data	99	95	94	94	94	93	90	100	99	99	96
Median Hb all patients**	108	110	114	111	109	111	111	110	115	119	111
% patients with Hb 100-120 g/L***	63.8	63.1	69.2	62.9	54.3	75.0	74.2	25.0	55.6	48.3	61.5
% patients with Hb >120 g/L***	13.6	13.5	17.9	18.0	17.1	10.8	11.3	50.0	29.6	44.9	19.9
Upper quartile***	115	117	118	118	117	116	114	124	123	125	118
Median Hb g/L***	108	109	113	110	109	110	108	116	114	119	110
Lower quartile***	101	100	107	102	98	103	103	105	106	108	102
Range g/L***	63 - 148	70 - 144	81 - 135	57 - 167	63 - 133	79 - 142	82 - 155	75 - 130	67 - 148	80 - 142	57 - 167

* The standards set for adults are not applicable to children.

** All patients with results except those with recent blood transfusion (n=1796).

*** UKRA standard. Hb 100-120 g/L on ESA therapy. Patients were excluded if there were no data, they had recently received a blood transfusion or were not receiving ESA therapy on the census date (n=1554).

Of the 1796 patients with Hb values, 1485 (82.7%) had Hb \geq 100g/L.

198 patients were confirmed as not receiving ESA therapy and had not recently received a blood transfusion. Of the 193 with data 11 (5.7%) had Hb <100g/L, 74 (38.3%) had Hb 100 - 120g/L and 108 (56.0%) had Hb >120g/L.

Data on ESA treatment (including patients confirmed as not receiving ESA) were available for 1814 (96.6%) patients. Using this information we were able to calculate the proportion of patients achieving the UKRA standard (Hb 100-120g/L) receiving ESA therapy on the census date. Of the 1554 patients confirmed as receiving ESA treatment and who had data and had not recently been transfused, 956 (61.5%) achieved the UKRA standard. Hb was <100g/L in 288 (18.5%) of patients, Hb was >120g/L in 310 (19.9%) and 144 (9.3%) had Hb >125g/L.

There is variation in practice across Scotland for ESA prescription when patients are diagnosed with malignancy; some units stop therapy whereas other take a more individualised approach. We have not taken this into account in our analyses.